These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 26711718

  • 1. Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses.
    Westover JB, Sefing EJ, Bailey KW, Van Wettere AJ, Jung KH, Dagley A, Wandersee L, Downs B, Smee DF, Furuta Y, Bray M, Gowen BB.
    Antiviral Res; 2016 Feb; 126():62-8. PubMed ID: 26711718
    [Abstract] [Full Text] [Related]

  • 2. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever.
    Mendenhall M, Russell A, Smee DF, Hall JO, Skirpstunas R, Furuta Y, Gowen BB.
    PLoS Negl Trop Dis; 2011 Oct; 5(10):e1342. PubMed ID: 22022624
    [Abstract] [Full Text] [Related]

  • 3. T-705 (favipiravir) inhibition of arenavirus replication in cell culture.
    Mendenhall M, Russell A, Juelich T, Messina EL, Smee DF, Freiberg AN, Holbrook MR, Furuta Y, de la Torre JC, Nunberg JH, Gowen BB.
    Antimicrob Agents Chemother; 2011 Feb; 55(2):782-7. PubMed ID: 21115797
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Favipiravir (T-705) inhibits Junín virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever.
    Gowen BB, Juelich TL, Sefing EJ, Brasel T, Smith JK, Zhang L, Tigabu B, Hill TE, Yun T, Pietzsch C, Furuta Y, Freiberg AN.
    PLoS Negl Trop Dis; 2013 Feb; 7(12):e2614. PubMed ID: 24386500
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever.
    Oestereich L, Rieger T, Neumann M, Bernreuther C, Lehmann M, Krasemann S, Wurr S, Emmerich P, de Lamballerie X, Ölschläger S, Günther S.
    PLoS Negl Trop Dis; 2014 May; 8(5):e2804. PubMed ID: 24786461
    [Abstract] [Full Text] [Related]

  • 7. Enhanced protection against experimental Junin virus infection through the use of a modified favipiravir loading dose strategy.
    Gowen BB, Westover JB, Sefing EJ, Van Wettere AJ, Bailey KW, Wandersee L, Komeno T, Furuta Y.
    Antiviral Res; 2017 Sep; 145():131-135. PubMed ID: 28780425
    [Abstract] [Full Text] [Related]

  • 8. Potential and action mechanism of favipiravir as an antiviral against Junin virus.
    Zadeh VR, Afowowe TO, Abe H, Urata S, Yasuda J.
    PLoS Pathog; 2022 Jul; 18(7):e1010689. PubMed ID: 35816544
    [Abstract] [Full Text] [Related]

  • 9. Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever.
    Gowen BB, Sefing EJ, Westover JB, Smee DF, Hagloch J, Furuta Y, Hall JO.
    Antiviral Res; 2015 Sep; 121():132-7. PubMed ID: 26186980
    [Abstract] [Full Text] [Related]

  • 10. Severe mammarenaviral disease in guinea pigs effectively treated by an orally bioavailable fusion inhibitor, alone or in combination with favipiravir.
    Westover JB, Naik S, Bailey KW, Wandersee L, Gantla VR, Hickerson BT, McCormack K, Henkel G, Gowen BB.
    Antiviral Res; 2022 Dec; 208():105444. PubMed ID: 36243175
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment.
    Scharton D, Bailey KW, Vest Z, Westover JB, Kumaki Y, Van Wettere A, Furuta Y, Gowen BB.
    Antiviral Res; 2014 Apr; 104():84-92. PubMed ID: 24486952
    [Abstract] [Full Text] [Related]

  • 15. Favipiravir (T-705), a novel viral RNA polymerase inhibitor.
    Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL.
    Antiviral Res; 2013 Nov; 100(2):446-54. PubMed ID: 24084488
    [Abstract] [Full Text] [Related]

  • 16. Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates.
    Madelain V, Duthey A, Mentré F, Jacquot F, Solas C, Lacarelle B, Vallvé A, Barron S, Barrot L, Mundweiler S, Thomas D, Carbonnelle C, Raoul H, de Lamballerie X, Guedj J.
    Antiviral Res; 2020 May; 177():104758. PubMed ID: 32135218
    [Abstract] [Full Text] [Related]

  • 17. Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.
    Madelain V, Guedj J, Mentré F, Nguyen TH, Jacquot F, Oestereich L, Kadota T, Yamada K, Taburet AM, de Lamballerie X, Raoul H.
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27736754
    [Abstract] [Full Text] [Related]

  • 18. Clinical Management of Argentine Hemorrhagic Fever using Ribavirin and Favipiravir, Belgium, 2020.
    Veliziotis I, Roman A, Martiny D, Schuldt G, Claus M, Dauby N, Van den Wijngaert S, Martin C, Nasreddine R, Perandones C, Mahieu R, Swaan C, Van Praet S, Konopnicki D, Morales MA, Malvy D, Stevens E, Dechamps P, Vlieghe E, Vandenberg O, Günther S, Gérard M.
    Emerg Infect Dis; 2020 Jul; 26(7):1562-1566. PubMed ID: 32271701
    [Abstract] [Full Text] [Related]

  • 19. Antiviral Effect of Favipiravir (T-705) against Measles and Subacute Sclerosing Panencephalitis Viruses.
    Hashimoto K, Maeda H, Miyazaki K, Watanabe M, Norito S, Maeda R, Kume Y, Ono T, Chishiki M, Suyama K, Sato M, Hosoya M.
    Jpn J Infect Dis; 2021 Mar 24; 74(2):154-156. PubMed ID: 32863356
    [Abstract] [Full Text] [Related]

  • 20. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.
    Safronetz D, Rosenke K, Westover JB, Martellaro C, Okumura A, Furuta Y, Geisbert J, Saturday G, Komeno T, Geisbert TW, Feldmann H, Gowen BB.
    Sci Rep; 2015 Oct 12; 5():14775. PubMed ID: 26456301
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.